参芪扶正注射液治疗晚期非小细胞肺癌化疗后骨髓抑制的Meta分析

<正>据国际癌症研究机构(international agency for research on cancer,IARC)统计,中国肺癌发生率居所有肿瘤中的第一位,其次为胃癌和肝癌1],其中非小细胞肺癌(non-small cell lung cancer,NSCLC)的发生率约85%2]。目前对于晚期非小细胞肺癌的治疗方案,主要以手术配合放化疗为主,然而许多患者在化疗过程中,会出现肝肾功能损伤、免疫力下降、骨

Meta-analysis of Shenqi Fuzheng Injection in Treating Advanced Non-small Cell Lung Cancer with Bone Marrow Suppression after Chemotherapy

Objective To systematically evaluate the effect of Shenqi Fuzheng Injection on myelosuppression after chemotherapy in patients with advanced non-small cell lung cancer. Methods By searching CNKI, Pubmed, Wan Fang Data, The Cochrane Library and other databases, the literature was screened according to the inclusion and exclusion criteria, the Cochrane risk bias assessment tool was used to evaluate the literature quality, and the RevMan 5.3 software was used for statistical analysis. Results Twelve studies were eventually included, including a total of 1057 patients. The statistical analysis showed that the patients with WBC, Hb, and PLT decrease in the experimental group after chemotherapy were significantly lower than those in the control group (P&lt;0.05). The bone marrow suppression in the experimental group was lower than that in the control group. Conclusion The results of the analysis show that Shenqi Fuzheng Injection can significantly improve bone marrow suppression in patients with advanced non-small cell lung cancer after chemotherapy. However, due to the low quality of the included literature, a large number of high-quality, large-sample randomized controlled trials are needed to confirm this.